ReviewCureus2025

Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review.

Dalia Tantawy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.